John B. Moriarty - Aug 4, 2025 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role: Chief Legal Officer
Signature: /s/ Michael F. MacLean, Attorney-in-Fact
Stock symbol: RNA
Transactions as of: Aug 4, 2025
Transactions value $: -$81,291
Form type: 4
Date filed: 8/5/2025, 05:27 PM
Previous filing: Jan 8, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Moriarty John B	Chief Legal Officer	C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO	/s/ Michael F. MacLean, Attorney-in-Fact	2024-08-05	0001564621

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNA	Common Stock	Sale	-$81.3K	-2.25K	-4.49%	$36.21	47.8K	Aug 4, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on August 1, 2025 and the sale of the resulting shares of common stock on August 4, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.
F2	This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.21. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on August 1, 2025 and the sale of the resulting shares of common stock on August 4, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.21. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.